REG - Schroders Cap Glbl - Quarterly NAV Announcement - 31 March 2025

Schroders Capital Global Innovation TrustAnnouncement

22/05/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250522:nRSV6817Ja&default-theme=true

RNS Number : 6817J  Schroders Capital Global Innovation  22 May 2025

Schroders Capital Global Innovation Trust plc

Q1 2025 Quarterly Net Asset Value

Schroders Capital Global Innovation Trust plc (the "Company") today announces
its net asset value ("NAV") as of 31 March 2025.

Summary

 * As of 31 March 2025, NAV per share stands at 21.86p, an increase of 9.6%
relative to the NAV per share as of 31 December 2024 (19.94p).

 * Performance over the quarter was positively impacted by the sale of Araris
Biotech ("Araris"), which was sold to Taiho Pharmaceutical Co. Ltd. for an
upfront payment of $400 million, with up to $750 million in near to long term
milestone payments. The Company's share of the proceeds received during the
quarter totalled £18.7 million. As of 31 March 2025, the investment in Araris
has delivered a 8.2x gross multiple of invested capital ("MoIC"), with the
potential to increase up to 20.2x with additional milestones.

 * Additionally, Anthos Therapeutics announced its acquisition by Novartis during
the quarter. The sale is expected to generate 1.9x gross MoIC on the upfront
payment and up to 3.2x with milestones. The transaction is expected to
complete during 2025.

 * The Company participated in Neurona Therapeutics latest funding rounding,
making a £0.7 million follow-on investment, which received approval from the
Board.

 * As of 31 March 2025, the Company had £30.2 million in cash and money market
(sterling liquidity) funds, £18.2 million in other net current assets to
reflect the proceeds from the sale of Araris Biotech received shortly after
the period end, and £2.0 million in liquid public equity investments.

 * The Company completed the share buyback programme in Q1 2025, purchasing 5.9
million shares for £0.6 million.

 * On 27 February 2025, shareholders voted in favour of the discontinuation
resolution and adoption of the revised investment objective and policy to
provide for the managed wind-down of the Company with an orderly realisation
of the Company's assets, including an initial return of capital.

 

 

Performance

The NAV as of 31 March 2025 was £176.8 million, an increase of 8.9% compared
to the NAV (£162.4 million) as of 31 December 2024. The NAV per share as of
31 March 2025 was 21.86p, an increase of 9.6% compared with the NAV per share
(19.94p) as of 31 December 2024. The difference between the NAV and NAV per
share movements is due to the share buybacks during the period.

 

 Attribution analysis (£m)                                  Private equity                  Public equity  Money market funds  Cash & cash equivalents      Other  NAV
                                                            Life sciences  Venture  Growth
 Fair value as at 31.12.24                                  20.8           31.9     74.7    4.0            29.7                1.9                          (0.6)  162.4
 + Investments                                              3.5            -        -       -              -                   (3.5)                        -      -
 - Realisations at value                                    (21.3)         -        (0.4)   -              (0.9)               22.6                         -      -
 +/- Fair value gains/(losses)                              17.7           (1.6)    0.2     (1.1)          0.3                 -                            -      15.5
 +/- Reclassified holdings*                                 0.9                             (0.9)          -                   -                            -      -
 - Repurchase and cancellation of the Company's own shares  -              -        -       -              -                   (0.6)                        -      (0.6)
 +/- Costs and other movements                              -              -        -       -              -                   (19.3)                       18.8   (0.5)
 Fair value as at 31.03.25                                  21.6           30.3     74.5    2.0            29.1                1.1                          18.2   176.8

(*Benevolent AI merger and conversion to Osaka)

The notable contribution to performance over the quarter was in the Company's
life sciences holdings, which saw a fair value gain of 85.1%, contributing a
10.9% increase to the overall NAV. This was primarily due to the sale of
Araris Biotech to Taiho Pharmaceuticals. Proceeds from the sale totalled
£18.7 million.

The Company's growth holdings saw a slight fair value increase of £0.2
million, contributing 0.1% to the overall NAV increase. This was driven
primarily by an upwards revaluation of AI Company II¹ following strong
performance, partially offset by downwards revaluation of AgroStar. AgroStar
was revalued to reflect the terms of a recent funding round, in which the
Company did not participate.

On the negative side, the venture holdings saw a fair value loss of £1.6
million during the quarter, decreasing overall NAV by (0.9)%. This was
primarily driven by a downwards revaluation of Federated Wireless due to a
decrease in valuation multiple to reflect movement in market comparables. This
was partially offset by an upwards revaluation in Nexeon.

The Company's public equity holdings saw a fair value loss of £1.1 million,
contributing (0.7)% to the overall NAV decline. This was driven by the fall in
value of the holding in Autolus Therapeutics, as the share price fell 41%
during the quarter. BenevolentAI delisted from Euronext Amsterdam as of 13
March 2025, following a shareholder-approved merger with Osaka Holdings.

Foreign Exchange

During the quarter, foreign exchange has a slight negative impact on NAV, with
the fair value of investments denominated in the US Dollar (USD) negatively
impacted by the appreciation of British pound sterling (GBP) relative to the
USD. Investments denominated in Euro (EUR) were positively impacted by the
slight depreciation of British pound sterling (GBP) relative to the Euro.

 

Cash, debt, and net current assets

As of 31 March 2025, the Company held £30.2 million in cash and money
market (sterling liquidity) funds and £18.2 million in other net current
assets to reflect the proceeds from the sale of Araris Biotech received
shortly after the period end.

¹ Actual name not disclosed due to confidentiality.

Investment activity

Realisations

During the quarter, the Company made realisations totalling £21.7 million,
comprising of £21.3 million to reflect proceeds from the sale of Araris,
before adjusting for the technical conversion of a convertible loan, resulting
in net realisation proceeds of £18.7 million, and a £0.4 million capital
distribution from Salica ET Fund.

Investments

During the quarter, the Company made a follow-on investment of £0.7 million
into Neurona Therapeutics, which received approval from the Board.

As a reminder, following the vote in favour of the discontinuation resolution
and change in investment objective and policy, aside from honouring any
existing contractual arrangements, the Board's prior written approval is
required for any further investment. The Company will not make any new
investments.

Top 10

The Company's top 10 holdings as of 31 March 2025 compared with the respective
value and percentage weighting as of 31 December 2024.

 Holding                   Strategy       Fair value as of 31 Dec 24 (£m)   % of NAV  Fair value as of 31 Mar 25 (£m)   % of NAV
 Atom Bank                 Growth         23.1                              14.2%     23.1                              13.1%
 Revolut                   Growth           14.6                            9.0%      14.1                              8.0%
 AI Company II             Growth         8.0                               4.9%      10.8                              6.1%
 Nexeon                    Venture        7.8                               4.8%      8.3                               4.7%
 Salica ET Fund            Growth         8.2                               5.0%      7.7                               4.4%
 Back Market               Growth         8.1                               5.0%      7.5                               4.2%
 AgroStar                  Growth         7.9                               4.9%      6.3                               3.6%
 Ada Health                Growth         4.2                               2.6%      4.3                               2.4%
 Anthos Therapeutics       Life sciences  3.6                               2.2%      4.2                               2.4%
 CeQur                     Life sciences  4.2                               2.6%      4.1                               2.3%
 Cash & equivalents                       31.6                              19.4%     30.2                              17.1%
 Other net current assets                 (0.6)                             (0.4%)    18.2                              10.3%

 

Outlook

Whilst the inherited assets in the portfolio continue to be a drag on NAV, the
Portfolio Manager is confident in the outlook of the new investment portfolio,
which currently stands at 1.2x MoIC and has seen two strong exits during the
first few months of 2025.

In total, Schroders Capital has made 19 new investments since being appointed
Investment Manager in 2019. The latest exits of Araris Biotech at 8.2x MoIC
(with the potential to increase to 20.2x MoIC with milestones), Anthos
Therapeutics at 1.9x MoIC (with the potential to increase to 3.4x MoIC with
milestones), build on the previous exits of Carmot Therapeutics at 3.2x MoIC
and Tessian at 1.1x MoIC.

On 27 February 2025, shareholders voted in favour of the discontinuation
resolution and adoption of the revised investment objective and policy to
provide for the managed wind-down of the Company with an orderly realisation
of the Company's assets, including an initial return of capital.

Taking into account the Company's current cash, including the upfront proceeds
from the sale of Araris, and existing commitments, the Board and the
Investment Manager anticipate the initial return of capital will be
approximately £30 million. We expect to publish a circular to shareholders
seeking approval of the required shareholder resolutions by 30 June 2025. A
General Meeting will be required, and the tender offer is likely to be open
for around 4 weeks to maximise the opportunity for shareholders to accept.

After the initial return of capital, we do not expect to continue meaningful
realisations until the 2026-2027 period.

We are closely monitoring the impact of the U.S. trade war and the associated
global market volatility. Although the initial measures are not expected to
significantly affect the portfolio, we are continually assessing the
longer-term implications for global capital markets in this fast-paced
environment.

 

Past performance is not a guide to future performance and may not be repeated.
The value of investments and the income from them may go down as well as up
and investors may not get back the amounts originally invested. The securities
shown above are for illustrative purposes only and are not to be considered a
recommendation to buy or sell.

 

 

Enquiries:

Schroder Investment Management Limited

   Katherine Fyfe (Company Secretary)          0207 658 3136
   Charlotte Banks (Press)                     0207 658 9063
   John Spedding (Head of Investment Trusts)   0207 658 3206

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NAVABMPTMTMTBLA